Last Updated: November 16, 2026

GAMMAPLEX Drug Profile

« Back to Dashboard


Summary for Tradename: GAMMAPLEX
High Confidence Patents:0
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for GAMMAPLEX
Recent Clinical Trials for GAMMAPLEX

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Isaac MelamedPhase 4
Bio Products LaboratoryPhase 4

See all GAMMAPLEX clinical trials

Pharmacology for GAMMAPLEX
Mechanism of ActionAntigen Neutralization
Physiological EffectPassively Acquired Immunity
Established Pharmacologic ClassHuman Immunoglobulin G
Chemical StructureImmunoglobulins
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and company disclosures
  4. These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for GAMMAPLEX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for GAMMAPLEX Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for GAMMAPLEX Derived from Patent Text Search

These patents were obtained by searching patent claims

GAMMAPLEX Market Dynamics, Patent Position, and Financial Trajectory

Last updated: October 31, 2026

GAMMAPLEX is a human intravenous immunoglobulin product supplied by Bio Products Laboratory Ltd. (BPL), now part of Kedrion Biopharma. Its commercial position is supported by recurring demand for immune globulin, physician familiarity, and the manufacturing barriers associated with plasma-derived biologics. Its financial trajectory cannot be isolated from public filings because Kedrion is privately held and does not report GAMMAPLEX revenue separately.

The principal risks are supply dependence on recovered plasma, competition from other IVIG brands, hospital and specialty-pharmacy purchasing pressure, and the possibility of biosimilar competition after biologic exclusivity has expired. Generic substitution through an ANDA is not available for GAMMAPLEX.

What is GAMMAPLEX and who manufactures it?

GAMMAPLEX is an intravenous immune globulin, human, made from pooled human plasma. It is marketed in the United States by BPL and manufactured within BPL’s plasma-derived product network. Kedrion acquired BPL in 2022, creating a larger plasma-products platform with operations spanning plasma collection, fractionation, purification and commercialization. [1]

Attribute GAMMAPLEX
Active ingredient Immune globulin intravenous, human
Product class Plasma-derived biologic
Primary dosage forms 5% and 10% intravenous solutions
U.S. regulatory pathway Biologics license application
Manufacturer and sponsor history BPL; BPL became part of Kedrion Biopharma
Core indications Primary humoral immunodeficiency and chronic immune thrombocytopenic purpura, depending on presentation and labeling
Substitution pathway No conventional ANDA generic pathway
Biosimilar pathway Potential 351(k) pathway
Public standalone revenue Not disclosed

GAMMAPLEX competes in the same broad IVIG category as GAMUNEX-C, Privigen, Gammagard Liquid, Octagam, Panzyga and Flebogamma. Product-level differentiation is limited because most products deliver pooled IgG, but clinical familiarity, purity profile, infusion tolerability, supply reliability, contracting and reimbursement determine purchasing decisions.

What FDA indications does GAMMAPLEX have?

GAMMAPLEX has been approved for replacement therapy in primary immunodeficiency and for treatment of chronic immune thrombocytopenic purpura in adults, subject to the specific product presentation and current FDA labeling. [2]

Primary immunodeficiency

The primary immunodeficiency market produces recurring demand because patients generally require repeated infusions over long treatment periods. This creates a more predictable volume base than acute-use indications.

Treatment frequency varies by patient, clinical response, body weight and payer authorization. Demand is therefore linked to the diagnosed patient population and treatment intensity rather than only to new prescriptions.

Chronic immune thrombocytopenic purpura

The ITP indication is more episodic. IVIG can be used when a rapid increase in platelet count is clinically required, including before procedures or during significant bleeding risk. This market contributes to utilization but is less predictable than long-term replacement therapy.

When does GAMMAPLEX lose exclusivity?

GAMMAPLEX’s U.S. biologic exclusivity period has expired.

FDA approved GAMMAPLEX in 2010. Under the Biologics Price Competition and Innovation Act, a reference biologic receives 12 years of reference-product exclusivity from first licensure, subject to statutory rules governing first licensure and patent certifications. The practical reference-product exclusivity period therefore ended around 2022. [3]

Milestone Approximate timing
FDA approval of GAMMAPLEX 2010
Twelve-year reference-product exclusivity Approximately 2022
Current status Post-exclusivity biologic
ANDA generic entry Not available
351(k) biosimilar entry Legally available, subject to FDA approval and commercial litigation

Expiration of regulatory exclusivity does not guarantee near-term competition. IVIG manufacturing requires qualified plasma supply, validated fractionation capacity, viral-clearance controls, extensive comparability data and specialized distribution. These requirements create higher entry barriers than those associated with conventional small-molecule generics.

What is the Orange Book status of GAMMAPLEX?

GAMMAPLEX is not an Orange Book small-molecule product. The FDA’s Orange Book primarily covers approved drug products and their associated patents under the Hatch-Waxman framework. Biologic reference products are tracked through FDA biologics records and the Purple Book rather than through a standard Orange Book patent-listing structure. [4]

This distinction has several commercial consequences:

  • A competitor cannot file a standard ANDA seeking automatic substitution for GAMMAPLEX.
  • A biosimilar applicant generally uses the Public Health Service Act section 351(k) pathway.
  • Patent disclosures, litigation and market-entry timing follow the BPCIA framework rather than ordinary Paragraph IV procedures.
  • Pharmacy substitution depends on FDA interchangeability determinations and state law, not simply on generic-equivalence status.

Are there Paragraph IV challenges to GAMMAPLEX?

No material, publicly established Paragraph IV challenge is associated with GAMMAPLEX’s U.S. approval because GAMMAPLEX is a biologic rather than an ANDA-eligible small-molecule drug.

A biosimilar applicant would instead participate in the BPCIA patent-information exchange and related litigation process. Publicly available information does not identify a major announced GAMMAPLEX biosimilar litigation campaign or a marketed FDA-approved GAMMAPLEX biosimilar.

What litigation affects GAMMAPLEX?

No major publicly documented U.S. patent litigation campaign involving GAMMAPLEX is identified in the principal public regulatory and corporate sources reviewed for this analysis. The absence of disclosed litigation does not eliminate potential process, formulation, manufacturing or trade-secret disputes, but it indicates no visible litigation-driven near-term launch event.

How strong is the GAMMAPLEX patent estate?

The commercial defensibility of GAMMAPLEX appears to rest more heavily on manufacturing capability, regulatory compliance, plasma access and customer relationships than on a publicly prominent patent estate.

Formulation patents

GAMMAPLEX’s value is not dependent solely on a single formulation claim. IVIG products can be protected by patents directed to:

  • Stabilizer systems and excipients
  • Protein concentration and solution characteristics
  • Viral inactivation and removal
  • Purification and fractionation processes
  • Container and delivery systems
  • Manufacturing controls and quality attributes

Publicly visible market information does not establish a currently decisive, GAMMAPLEX-specific U.S. formulation patent blocking biosimilar entry. A biosimilar applicant would still need to evaluate BPL and Kedrion patents, manufacturing patents, process know-how and potential regulatory exclusivity issues.

Method-of-use patents

The core GAMMAPLEX indications are established therapeutic uses rather than a clearly disclosed late-life-cycle method-of-use strategy. Method-of-use patents, where enforceable, could affect particular dosing regimens or patient subgroups, but they would not necessarily prevent a biosimilar from entering for non-patented indications.

Manufacturing and trade-secret barriers

Manufacturing barriers are more important than conventional patent protection in the IVIG market. Relevant barriers include:

  1. Access to qualified human plasma.
  2. Large-scale fractionation and purification capacity.
  3. Viral safety and pathogen-reduction validation.
  4. Batch-to-batch consistency for pooled plasma products.
  5. FDA inspection history and compliance systems.
  6. Cold-chain logistics and specialty distribution.
  7. Pharmacovigilance and post-market quality controls.

These barriers can delay or discourage entry even after patent and exclusivity rights expire.

Which companies compete with GAMMAPLEX?

GAMMAPLEX competes in a concentrated global IVIG market. Major competitors include products from Grifols, CSL Behring, Takeda, Octapharma, Pfizer, Kedrion and other plasma-product companies.

Product Company Competitive relevance
GAMUNEX-C Grifols Large U.S. IVIG franchise with broad provider familiarity
Privigen CSL Behring Major liquid IVIG product with extensive specialty distribution
Gammagard Liquid Takeda Established IVIG brand with strong immunology presence
Octagam Octapharma Competes across replacement and immunomodulatory uses
Panzyga Pfizer Established IVIG competitor with U.S. commercialization
Flebogamma DIF Grifols Global plasma-derived immunoglobulin brand
GAMMAPLEX BPL/Kedrion Smaller commercial position relative to the largest multinational IVIG brands

The competitive basis is primarily supply availability, contract terms, hospital formulary position, infusion-center experience and payer coverage. Clinical differentiation exists, but it is usually less decisive than dependable supply and total treatment economics.

What market dynamics are driving GAMMAPLEX sales?

The IVIG market has durable demand but recurring supply constraints.

Plasma supply

Plasma is the limiting input for most IVIG products. Collection volumes depend on donor recruitment, center operations, compensation, regulatory requirements and geographic restrictions. A disruption in plasma collection can affect product availability months later because fractionation and release cycles are lengthy.

Kedrion’s ownership of BPL gives GAMMAPLEX access to a broader corporate platform than BPL had as a standalone supplier. The commercial benefit depends on how Kedrion allocates plasma, production slots and sales resources among its products.

Demand growth

Demand is supported by:

  • Greater diagnosis of primary immunodeficiency.
  • Aging populations and increased use of immunomodulatory therapy.
  • Expanded physician familiarity with IVIG.
  • Chronic use in selected neurologic, hematologic and immunologic disorders.
  • Continued treatment of patients who are poor candidates for alternative therapies.

Demand can also be reduced by payer controls, subcutaneous immunoglobulin conversion and efforts to reserve IVIG for evidence-supported indications.

Pricing and reimbursement

IVIG pricing is shaped by acquisition cost, dose, site of care, payer contracting, handling fees and administration economics. Hospitals and specialty distributors may accept a product with lower price or better supply terms even when several clinically similar IVIG products are available.

GAMMAPLEX’s financial performance is therefore likely to reflect net price and volume after rebates rather than list price alone. Public sources do not disclose brand-level net pricing.

What is GAMMAPLEX’s financial trajectory?

Standalone GAMMAPLEX revenue is not publicly reported. Kedrion is privately held, and BPL financial disclosures do not provide a consistent, detailed U.S. brand-level revenue series for GAMMAPLEX.

The most defensible financial assessment is directional:

Period Financial interpretation
2010-2018 Established product phase, supported by FDA approval and recurring IVIG demand
2019-2021 Mature-brand phase with exposure to plasma supply, reimbursement and competitive pressure
2022 Ownership transition into Kedrion; potential benefits from broader operational scale
2023 onward Post-exclusivity period; revenue depends on supply execution, contracting and biosimilar defense
Medium term Stable or modest-growth potential in a growing IVIG category, offset by pricing and input-cost pressure

GAMMAPLEX is unlikely to be a major disclosed earnings driver on the scale of the largest global IVIG brands. Its strategic value is more likely tied to portfolio breadth, manufacturing utilization and customer retention within Kedrion’s plasma-derived business.

What generic or biosimilar launch risks exist?

The immediate generic-launch risk is low because ANDA substitution is unavailable. The relevant risk is biosimilar competition.

Biosimilar risk factors

A potential GAMMAPLEX biosimilar competitor would face:

  • Clinical and analytical comparability requirements.
  • Reference-product sourcing and characterization.
  • Manufacturing scale-up.
  • Plasma procurement and donor-network requirements.
  • FDA inspection and release controls.
  • Potential BPCIA patent disputes.
  • Contracting against established IVIG brands.
  • The need to secure payer and provider adoption.

The risk is therefore better characterized as medium-term strategic erosion rather than an imminent automatic substitution event.

A biosimilar could still pressure GAMMAPLEX through hospital tenders, specialty-distributor contracting and payer preference even without an interchangeability designation. The commercial impact would depend on whether the entrant has sufficient plasma capacity and whether it can offer reliable supply at a meaningful discount.

How does GAMMAPLEX compare with competing IVIG products?

GAMMAPLEX has the standard strengths and weaknesses of a mature IVIG brand.

Factor GAMMAPLEX position
Clinical demand Supported by recurring primary immunodeficiency use
Regulatory maturity Long-established FDA-approved product
Patent exclusivity No longer the primary barrier
Manufacturing barrier Significant because of plasma and fractionation requirements
Brand scale Smaller than leading global IVIG franchises
Supply leverage Improved by Kedrion ownership, but dependent on network capacity
Biosimilar exposure Possible, but entry is difficult
Switching risk Moderate where payers or providers prioritize cost
Price sensitivity High in institutional and distributor channels
Revenue transparency Low because standalone product sales are not disclosed

What are the key commercial scenarios for GAMMAPLEX?

Base case

GAMMAPLEX maintains a stable position in the IVIG market, with volume supported by recurring immunodeficiency demand. Revenue grows modestly with category demand but faces pricing pressure and costs associated with plasma procurement.

Upside case

Kedrion improves supply reliability, expands contracting coverage and uses its broader portfolio to increase provider access. GAMMAPLEX gains share in accounts seeking a dependable secondary or alternative IVIG supplier.

Downside case

Plasma shortages, manufacturing interruptions, payer exclusion or aggressive competitor contracting reduce volume. A biosimilar or lower-cost IVIG entrant increases price pressure after establishing reliable supply.

Key Takeaways

  • GAMMAPLEX is a plasma-derived IVIG product originally developed and commercialized by BPL.
  • BPL became part of Kedrion Biopharma in 2022.
  • FDA reference-product exclusivity has expired, but conventional generic substitution is unavailable.
  • No material Paragraph IV challenge is expected because GAMMAPLEX is regulated as a biologic.
  • Biosimilar competition is legally possible but operationally difficult.
  • The product’s most important defenses are plasma access, manufacturing capacity, regulatory compliance and supply reliability.
  • Kedrion does not publicly disclose standalone GAMMAPLEX revenue.
  • Financial performance is likely to be stable or modestly growing at the category level, with pressure from procurement costs, payer negotiations and competing IVIG products.
  • The main investment and licensing question is not whether GAMMAPLEX has long patent life. It is whether Kedrion can maintain competitive supply and contracting economics in a capacity-constrained IVIG market.

FAQs

Is GAMMAPLEX interchangeable with other IVIG products?

No. IVIG products are not automatically interchangeable merely because they contain human immunoglobulin. Substitution depends on product-specific regulatory status, prescriber decisions, payer rules and applicable state law.

Can a company launch a generic version of GAMMAPLEX?

No conventional ANDA generic can be approved for GAMMAPLEX. A competing company would generally need to pursue the FDA’s 351(k) biosimilar pathway or submit a separate biologics license application.

Does Kedrion report GAMMAPLEX sales separately?

No publicly available Kedrion reporting provides a reliable standalone GAMMAPLEX revenue figure. Kedrion is privately held, and product-level revenue is not reported in the detail required for a verified financial time series.

Is GAMMAPLEX exposed to subcutaneous immunoglobulin competition?

Yes. Subcutaneous immunoglobulin can replace IVIG for selected patients, especially in chronic replacement therapy. The substitution risk is lower in acute immunomodulatory uses where intravenous administration is clinically preferred.

What is the largest long-term risk to GAMMAPLEX value?

The largest long-term risk is a combination of plasma-supply disruption and contracting pressure from larger IVIG suppliers. Biosimilar entry is a secondary risk because manufacturing and supply requirements make rapid market penetration difficult.

References

  1. Kedrion Biopharma. (2022). Kedrion Biopharma completes acquisition of Bio Products Laboratory. https://www.kedrion.com
  2. U.S. Food and Drug Administration. (2024). GAMMAPLEX prescribing information. Bio Products Laboratory. https://www.accessdata.fda.gov
  3. U.S. Food and Drug Administration. (2024). Biologics Price Competition and Innovation Act: Reference product exclusivity. https://www.fda.gov
  4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.